chronic heart failure with reduced ejection fraction (NYHA Class II)

DBCOND0025714Cardiovascular Diseases

chronic heart failure with reduced ejection fraction (NYHA Class II) is the indication for 8 drugs in DrugBank. It is covered by 8 curated, structured indications.

Also known as: NYHA Class II Heart Failure · NYHA Class II Congestive Heart Failure · Heart Failure NYHA Class II
Classified under: Cardiovascular Diseases
Indicated drugs: Candesartan cilexetil
Eplerenone
Ferric carboxymaltose
Furosemide
Iobenguane sulfate I-123
Metoprolol
Perindopril
Valsartan

Resolves to

Vocabularies

SNOMED CT48447003MedDRA10007558UMLSC0264716

What you can answer from here — as of November 01, 2026

8Indicated drugsWith each drug's targets and mechanism

Listed above

8Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

10Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for chronic heart failure with reduced ejection fraction (NYHA Class II) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account